Biogened SA
19.70
PLN
0.00
(0.00%)
Biogened SA
NEWCONNECT:BGD
(NewConnect)
Recent
price
19.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Biogened S.A. is a Poland-based pharmaceutical and dermocosmetics company that develops, manufactures, and distributes specialized skincare treatments, generic pharmaceuticals, dietary supplements, and medical devices. The company operates primarily through its flagship dermo-cosmetic brand, Dermedic, offering clinically tested formulations engineered for sensitive, allergic, and problematic skin conditions. Biogened S.A. categorizes its core product and service offerings across specialized dermatological lines and healthcare segments, including Hydrain3 Hialuro for intensive dermal hydration and skin barrier repair; Cicatopy for the therapeutic management of atopic, eczematous, and extremely dry skin; Normacne for antibacterial care and the treatment of acne-prone skin; Capilarte for dermatological scalp and trichological hair therapies; Melumin for hyperpigmentation reduction and skin tone correction; Oilage for anti-aging and mature skin regeneration; Redness Calm and Angio for skin with rosacea and fragile capillaries; Sunbrella for broad-spectrum UVA, UVB, VL, and IR photoprotection; Dermedic Baby for pediatric dermatological care; prescription (Rx) and over-the-counter (OTC) generic pharmaceuticals; dietary supplements for metabolic, digestive, and immunological health; and contract manufacturing and laboratory formulation services operating under Good Manufacturing Practice (GMP) standards. Biogened S.A. serves pharmacy chains, pharmaceutical wholesalers, medical clinics, specialized cosmetic retailers, and direct-to-consumer e-commerce channels across Poland and more than 40 international markets throughout Europe, the Middle East, and Asia. Founded in 1949 and headquartered in Łódź, Poland, Biogened S.A. is publicly traded on the NewConnect market of the Warsaw Stock Exchange under the ticker symbol BGD. In recent developments, Biogened S.A. has expanded its international footprint by entering new distribution partnerships across European and Middle Eastern pharmacy retail networks, broadened the Dermedic line with advanced barrier-restoration and anti-pollution product launches, modernized its GMP-compliant manufacturing and testing infrastructure to enhance production capacity, and renewed its bank credit facilities to support working capital and sustained export expansion.